Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
114 participants
INTERVENTIONAL
2015-04-01
2017-07-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Neoadjuvant Chemotherapy for Patients With Advanced Gastric Cancer in ERAS Programs for Radical Gastrectomy
NCT03238404
Perioperative Chemoradiotherapy for Potentially Resectable Gastric Cancer
NCT00420394
A Phase II Study of Total Neoadjuvant Therapy for Locally Advanced Gastric Cancer
NCT04062058
Optimizing the Strategy for Preoperative Chemotherapy in Locally Advanced Gastric/Gastroesophageal Cancer
NCT02725424
A Randomized Phase III Study of Adjuvant Chemotherapy With or Without Chemo-radiotherapy in Patients With Local Advanced Gastric Cancer After D2 Resection.
NCT02648841
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ERAS group
Patients will undergo the ERAS programs.
ERAS group
ERAS is the name of a procedure. Patients in this group need receive the ERAS procedure instead of one drug.
SC group
Patients will undergo the SC group.
SC group
Patients were managed in accordance with SC programs during the perioperative period. SC programs were used daily in our center and were still routinely used in most of the other hospitals in China.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ERAS group
ERAS is the name of a procedure. Patients in this group need receive the ERAS procedure instead of one drug.
SC group
Patients were managed in accordance with SC programs during the perioperative period. SC programs were used daily in our center and were still routinely used in most of the other hospitals in China.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age older than 18 and younger than 75 years.
3. American Society of Anesthesiologists (ASA) class: I-III.
4. Participants can describe the symptom objectively and cooperate actively.
5. Written informed consent.
Exclusion Criteria
2. Patients with ischemic heart disease, cerebrovascular disease and peripheral vascular disease, or cardiac function \> II (NYHA)
3. Patients with complications (bleeding, perforation and obstruction) caused by gastric cancer.
4. Patients with severe liver and renal dysfunction (Child - Pugh ≥ 10; Cr \< 25 ml/min).
5. Patients who require simultaneous surgery for other diseases.
6. Patients who received upper abdominal surgery previously.
7. Pregnant or breast-feeding women.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
JIANG Zhi-Wei
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
JIANG Zhi-Wei
Vice director of Research Institute of General Surgery
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zhiwei JIANG, MD
Role: PRINCIPAL_INVESTIGATOR
Jinling Hospital, Medical School of Nanjing University
Jian ZHAO, MD
Role: STUDY_DIRECTOR
Jinling Hospital, Medical School of Nanjing University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Jinling Hospital, Medical School of Nanjing University
Nanjing, Jiangsu, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
8150041701
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.